IDiyas

For the Inventor, By the Inventor

Kyoto, Japan

Koichi Igarashi

USPTO Granted Patents = 20

 

Average Co-Inventor Count = 3.2

ph-index = 5

Forward Citations = 84(Granted Patents)


Company Filing History:

goldMedal19 out of 1,858 
 
Takeda Chemical Industries, Inc.
 patents
silverMedal3 out of 222 
 
National Cancer Center
 patents
bronzeMedal2 out of 1,036 
 
Children's Medical Center Corporation
 patents
where one patent can have more than one assignee

Years Active: 1990-2004

Loading Chart...
Loading Chart...
20 patents (USPTO):Explore Patents
1. 6825165 - Betacellulin modification (2004-11-30),
2. 6013784 - Nucleic acids encoding HST 2 muteins (2000-01-11),
3. 6013762 - Smooth muscle mitogen and isolated DNA coding therefor (2000-01-11),
4. 5981197 - Monoclonal antibody, hybridoma, their production and use thereof (1999-11-09),
5. 5886141 - Smooth muscle mitogen peptides and DNA coding therefor (1999-03-23),
6. 5874247 - Protein disulfide isomerase and method of using (1999-02-23),
7. 5858779 - Monoclonal antibody, hybridoma, their production and use thereof (1999-01-12),
8. 5852177 - Basic fibroblast growth factor (bFGF) muteins (1998-12-22),
9. 5700678 - Protein disulfide-isomerase and production thereof (1997-12-23),
10. 5679550 - Hst-2 muteins, pharmaceutical compositions and kits comprising same, and (1997-10-21),
11. 5639862 - Deletion muteins of hst-1 (1997-06-17),
12. 5639664 - Method for producing human nerve growth factor 2 (1997-06-17),
13. 5559093 - N-terminally truncated hst-1 is a platelet-increasing factor (1996-09-24),
14. 5478740 - Hybridomas and monoclonal antibodies which specifically bind human basic (1995-12-26),
15. 5464943 - DNA encoding glycosylated FGF and production thereof (1995-11-07),

Title: The Innovations of Koichi Igarashi

Introduction

Koichi Igarashi is a prominent inventor based in Kyoto, Japan, renowned for his contributions to medical science and biotechnology. With a portfolio of 20 patents to his name, Igarashi's work focuses on the development of therapeutic agents, particularly in the field of diabetes treatment and smooth muscle cell proliferation.

Latest Patents

Among his latest patents, Igarashi's work on Betacellulin modification is particularly noteworthy. This invention explores the potential of betacellulin mutein or its salt as a therapeutic drug for diabetes. The innovation maintains intact BTC activity while reducing EGF activity and addressing antigenicity-related concerns. Another significant patent is the development of a recombinant non-glycosylated mammalian growth factor (BTC-GF). This factor stimulates the proliferation of human smooth muscle cells, showcasing its potential in regenerative medicine.

Career Highlights

Throughout his career, Koichi Igarashi has held significant positions in major organizations. He has worked with Takeda Chemical Industries, Inc., a leader in pharmaceutical innovation. Additionally, he served as the President of the National Cancer Center, contributing to advancements in cancer research and treatment methodologies.

Collaborations

Igarashi has collaborated with esteemed colleagues such as Tsutomu Kurokawa and Reiko Sasada. These partnerships have facilitated groundbreaking research and the advancement of patented technologies that address critical health challenges.

Conclusion

Koichi Igarashi’s innovative spirit and dedication to scientific research have made significant impacts in the fields of biotechnology and medicine. His patents continue to influence therapeutic strategies and inspire future generations of inventors in the quest for better health solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…